Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
The purpose of the randomized double-blind placebo-controlled trial was to assess the effectiveness of the synbiotic preparation (Lactobacillus rhamnosus FloraActive™ 19070-2 + Lactobacillus acidophilus DSMZ 32418 + Bifidobacterium lactis DSMZ 32269 + Bifidobacterium longum DSMZ 32946 + Bifidobacterium bifidum DSMZ 32403 + fructooligosaccharides) in adult patients with diarrhea-dominant IBS (IBS-D).
Except for Lactobacillus rhamnosus FloraActive™ 19070-2, the strain names do not seem to be clear, which is why only the species are stated in the study's title.
The study included eighty patients with moderate and severe IBS-D who were randomized to receive synbiotics or placebo for eight weeks.
Primary outcome measures:
Improvement or worsening of IBS global symptoms using Global Improvement Scale (IBS-GIS)
Cha…